Abstract
The immune checkpoint LAG-3 (lymphocyte activation gene 3) or CD223/FDC protein is located on chromosome 12 of the human genome. Enhancement of antitumor response is by modulation of signaling pathways between T lymphocytes and antigen-presenting cells and reestablishment of cytotoxic T lymphocyte activity. In recent years, LAG-3 has been taken into consideration as a prognostic tumor marker for therapy of cancer because it has turned into a potential target for immunotherapy. This book chapter aims to analyze the molecular constitution and connections of LAG 3 including its expression, signaling pathways involved in its clinical trial results have shown that LAG-3 blocking Monoclonal Antibody, Relatlimab, Nivolumab, and Ipilimumab are both effective and safe. Investigation of the functional characteristics of LAG-3 may allow the development of better, non-invasive therapies for lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anagnostou VK, Brahmer JR (2015) Cancer Immunotherapy: a future paradigm shift in the treatment of non–small cell lung cancer. Clin Cancer Res 21(5):976–984. https://doi.org/10.1158/1078-0432.CCR-14-1187
Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44(5):989–1004. https://doi.org/10.1016/j.immuni.2016.05.001
Ascierto PA, Bono P, Bhatia S, Melero I, Nyakas MS, Svane I-M, Larkin J, Gomez-Roca C, Schadendorf D, Dummer R, Marabelle A, Hoeller C, Maurer M, Harbison CT, Mitra P, Suryawanshi S, Thudium K, Muñoz Couselo E (2017) Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in Pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (Mel Prior IO) in all-comer and biomarker-enriched populations. Ann Oncol 28:v611–v612. https://doi.org/10.1093/annonc/mdx440.011
Ascione A, Arenaccio C, Mallano A, Flego M, Gellini M, Andreotti M, Fenwick C, Pantaleo G, Vella S, Federico M (2019) Development of a novel human phage display-derived anti-LAG3 ScFv antibody targeting CD8+ T lymphocyte exhaustion. BMC Biotechnol 19(1):67. https://doi.org/10.1186/s12896-019-0559-x
Avice M-N, Sarfati M, Triebel F, Delespesse G, Demeure CE (1999) Lymphocyte activation Gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-α and IL-12 production by monocytes and dendritic cells. J Immunol 162(5):2748–2753. https://doi.org/10.4049/jimmunol.162.5.2748
Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis 16(1):223–249. https://doi.org/10.1146/annurev-pathol-042020-042741
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
Brignone C, Escudier B, Grygar C, Marcu M, Triebel F (2009) A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15(19):6225–6231. https://doi.org/10.1158/1078-0432.CCR-09-0068
Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, Bousetta N, Medioni J, Gligorov J, Grygar C, Marcu M, Triebel F (2010) First-line Chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8(1):71. https://doi.org/10.1186/1479-5876-8-71
Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, Parmiani G, Belli F, Rivoltini L, Castelli C (2010) LAG-3 expression defines a subset of CD4+CD25highFoxp3+ regulatory T cells that are expanded at tumor sites. J Immunol 184(11):6545–6551. https://doi.org/10.4049/jimmunol.0903879
Chen J, Chen Z (2014) The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol 31(8):82. https://doi.org/10.1007/s12032-014-0082-9
Chocarro L, Blanco E, Arasanz H, Fernández-Rubio L, Bocanegra A, Echaide M, Garnica M, Ramos P, Fernández-Hinojal G, Vera R, Kochan G, Escors D (2022) Clinical landscape of LAG-3-targeted therapy. Immuno Oncol Technol 14:100079. https://doi.org/10.1016/j.iotech.2022.100079
Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent Progress and potential biomarkers. Exp Mol Med 50(12):1–11. https://doi.org/10.1038/s12276-018-0191-1
Dirix L, Triebel F (2019) AIPAC: a phase IIb study of Eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer. Future Oncol 15(17):1963–1973. https://doi.org/10.2217/fon-2018-0807
Dumic J, Dabelic S, Flögel M (2006) Galectin-3: an open-ended story. Biochim Biophys Acta BBA-Gen Subj 1760(4):616–635. https://doi.org/10.1016/j.bbagen.2005.12.020
Fahrer AM, Konigshofer Y, Kerr EM, Ghandour G, Mack DH, Davis MM, Chien Y (2001) Attributes of γδ intraepithelial lymphocytes as suggested by their transcriptional profile. Proc Natl Acad Sci U S A 98(18):10261
Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F, Di Serio C, Bacchetta R, Andreani M, Brockmann L, Gregori S, Flavell RA, Roncarolo M-G (2013) Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19(6):739–746. https://doi.org/10.1038/nm.3179
Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, Gill D, Marlton P, Seymour J, Khanna R (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108(7):2280–2289. https://doi.org/10.1182/blood-2006-04-015164
Hald SM, Rakaee M, Martinez I, Richardsen E, Al-Saad S, Paulsen E-E, Blix ES, Kilvaer T, Andersen S, Busund L-T, Bremnes RM, Donnem T (2018) LAG-3 in non–small-cell lung cancer: expression in primary tumors and metastatic lymph nodes is associated with improved Survival. Clin Lung Cancer 19(3):249–259.e2. https://doi.org/10.1016/j.cllc.2017.12.001
Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, Triebel F, Charron D, Aoudjit F, Al-Daccak R, Michel L (2011) MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 186(9):5173–5183. https://doi.org/10.4049/jimmunol.1002050
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466
Hoffmann MM, Slansky JE (2020) T-cell receptor affinity in the age of cancer immunotherapy. Mol Carcinog 59(7):862–870. https://doi.org/10.1002/mc.23212
Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DAA (2004) Role of LAG-3 in regulatory T cells. Immunity 21(4):503–513. https://doi.org/10.1016/j.immuni.2004.08.010
Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, Maigret B, Dréano M, Triebel F (1997) Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci 94(11):5744–5749. https://doi.org/10.1073/pnas.94.11.5744
Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F (1995) CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation Gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 25(9):2718–2721. https://doi.org/10.1002/eji.1830250949
Huard B, Tournier M, Hercend T, Triebel F, Faure F (1994) Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol 24(12):3216–3221. https://doi.org/10.1002/eji.1830241246
Iouzalen N, Andreae S, Hannier S, Triebel F (2001) LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the downregulation of the CD3/TCR activation pathway. Eur J Immunol 31(10):2885–2891. https://doi.org/10.1002/1521-4141(2001010)31:10<2885::aid-immu2885>3.0.co;2-2
Jenkins S, Wesolowski R, Gatti-Mays ME (2021) Improving breast cancer responses to immunotherapy—a search for the Achilles heel of the tumor microenvironment. Curr Oncol Rep 23(5):55. https://doi.org/10.1007/s11912-021-01040-y
Jiang H, Ni H, Zhang P, Guo X, Wu M, Shen H, Wang J, Wu W, Wu Z, Ding J, Tang R, Zhou S, Chen B, Yu M, **g H, Liu J (2021) PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Onco Targets Ther 10(1):1943180. https://doi.org/10.1080/2162402X.2021.1943180
Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K (2005) Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol 35(7):2081–2088. https://doi.org/10.1002/eji.200526090
Li Q, Huang Q, Cheng S, Wu S, Sang H, Hou J (2019) Circ_ZNF124 promotes non-small cell lung cancer progression by abolishing MiR-337-3p mediated downregulation of JAK2/STAT3 signaling pathway. Cancer Cell Int 19(1):291. https://doi.org/10.1186/s12935-019-1011-y
Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, Flores M, Li N, Schweighoffer E, Greenberg S, Tybulewicz V, Vignali D, Clynes R (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation Gene-3 engagement of MHC class II. J Immunol 180(9):5916–5926. https://doi.org/10.4049/jimmunol.180.9.5916
Liu W, Tang L, Zhang G, Wei H, Cui Y, Guo L, Gou Z, Chen X, Jiang D, Zhu Y, Kang G, He F (2004) Characterization of a novel C-type lectin-like gene, LSECtin. J Biol Chem 279(18):18748–18758. https://doi.org/10.1074/jbc.M311227200
Lui Y, Davis SJ (2018) LAG-3: a very singular immune checkpoint. Nat Immunol 19(12):1278–1279. https://doi.org/10.1038/s41590-018-0257-1
Ma Q-Y, Huang D-Y, Zhang H-J, Wang S, Chen X-F (2017) Function and regulation of LAG3 on CD4+CD25- T cells in non-small cell lung cancer. Exp Cell Res 360(2):358–364. https://doi.org/10.1016/j.yexcr.2017.09.026
Macon-Lemaitre L, Triebel F (2005) The negative regulatory function of the lymphocyte-activation Gene-3 co-receptor (CD223) on human T cells. Immunology 115(2):170–178. https://doi.org/10.1111/j.1365-2567.2005.02145.x
Mao X, Ou MT, Karuppagounder SS, Kam T-I, Yin X, **ong Y, Ge P, Umanah GE, Brahmachari S, Shin J-H, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonçalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DAA, Dawson VL, Ko HS, Dawson TM (2016) Pathological α-Synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353(6307):aah3374. https://doi.org/10.1126/science.aah3374
Maruhashi T, Okazaki I, Sugiura D, Takahashi S, Maeda TK, Shimizu K, Okazaki T (2018) LAG-3 inhibits the activation of CD4+ T cells that recognize stable PMHCII through its conformation-dependent recognition of PMHCII. Nat Immunol 19(12):1415–1426. https://doi.org/10.1038/s41590-018-0217-9
Maruhashi T, Sugiura D, Okazaki I, Okazaki T (2020) LAG-3: from molecular functions to clinical applications. J Immunother Cancer 8(2):e001014. https://doi.org/10.1136/jitc-2020-001014
Mastrangeli R, Micangeli E, Donini S (1996) Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (GENE-CAPTURE PCR). Anal Biochem 241(1):93–102. https://doi.org/10.1006/abio.1996.0382
McLane LM, Abdel-Hakeem MS, Wherry EJ (2019) CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol 37(1):457–495. https://doi.org/10.1146/annurev-immunol-041015-055318
Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F (2022) News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Semin Cancer Biol 79:18–43. https://doi.org/10.1016/j.semcancer.2020.07.001
Nurgalieva AK, Safina S, Shakirova E, Filonenko V, Skripova V, Bulatova L, Savenkova D, Bogdanov M, Kiyamova R (2021) 53P expression of sodium-dependent phosphate transporter NaPi2b is downregulated in malignant ovarian tumors after neoadjuvant chemotherapy. Ann Oncol 32:S1361–S1362. https://doi.org/10.1016/j.annonc.2021.08.2049
Okamura T, Yamamoto K, Fujio K (2018) Early growth response gene 2-expressing CD4+LAG3+ regulatory T cells: the therapeutic potential for treating autoimmune diseases. (“early growth response gene 2-expressing CD4 - Frontiers”). Front Immunol 9:340. https://doi.org/10.3389/fimmu.2018.00340
Poorebrahim M, Melief J, Pico de Coaña Y, Wickström LS, Cid-Arregui A, Kiessling R (2021) Counteracting CAR T Cell Dysfunction. (“TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging ...—nature”). Oncogene 40(2):421–435. https://doi.org/10.1038/s41388-020-01501-x
Previte DM, Martins CP, O’Connor EC, Marre ML, Coudriet GM, Beck NW, Menk AV, Wright RH, Tse HM, Delgoffe GM, Piganelli JD (2019) Lymphocyte activation Gene-3 maintains mitochondrial and metabolic quiescence in naive CD4+ T cells. Cell Rep 27(1):129–141.e4. https://doi.org/10.1016/j.celrep.2019.03.004
Prigent P, El Mir S, Dréano M, Triebel F (1999) Lymphocyte activation Gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol 29(12):3867–3876. https://doi.org/10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E
Puhr HC, Ilhan-Mutlu A (2019) New emerging targets in cancer immunotherapy: the role of LAG3. ESMO Open 4(2):e000482. https://doi.org/10.1136/esmoopen-2018-000482
Qin S, Xu L, Yi M, Yu S, Wu K, Luo S (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18(1):155. https://doi.org/10.1186/s12943-019-1091-2
Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A, Romero P, Speiser DE, Triebel F, Leyvraz S, Harari A (2014) MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after Lymphodepletion: results of a phase I trial. J Transl Med 12(1):97. https://doi.org/10.1186/1479-5876-12-97
Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA (2019) Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol 42:101305. https://doi.org/10.1016/j.smim.2019.101305
Sordo-Bahamonde C, Lorenzo-Herrero S, González-Rodríguez AP, Payer ÁR, González-García E, López-Soto A, Gonzalez S (2021) LAG-3 blockade with Relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia. Cancers 13(9):2112. https://doi.org/10.3390/cancers13092112
Triebel F (2003) LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 24(12):619–622. https://doi.org/10.1016/j.it.2003.10.001
Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T (1990) LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 171(5):1393–1405. https://doi.org/10.1084/jem.171.5.1393
Wang J, Asch AS, Hamad N, Weickhardt A, Tomaszewska-Kiecana M, Dlugosz-Danecka M, Pylypenko H, Bahadur S, Ulahannan S, Koucheki J, Sun J, Li H, Chen F, Zhang X, Muth J, Kaminker P, Moore P, Sumrow BJ (2020) A phase 1, open-label study of MGD013, a bispecific DART® molecule binding PD-1 and LAG-3 in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 136(Supplement 1):21–22. https://doi.org/10.1182/blood-2020-139868
Wang J, Meijers R, **ong Y, Liu J, Sakihama T, Zhang R, Joachimiak A, Reinherz EL (2001) Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc Natl Acad Sci U S A 98:10799
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L (2019) Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176(1–2):334–347.e12. https://doi.org/10.1016/j.cell.2018.11.010
Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG (2013) A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Investig New Drugs 31(3):707–713. https://doi.org/10.1007/s10637-012-9866-y
Weber S, Karjalainen K (1993) Mouse CD4 binds MHC class II with extremely low affinity. (“the structural basis of CD4 — MHC class II interactions …—springer”). Int Immunol 5(6):695–698. https://doi.org/10.1093/intimm/5.6.695
White AM, Wraith DC (2016) Tr1-like T cells–an enigmatic regulatory T cell lineage. Front Immunol 7:7. https://doi.org/10.3389/fimmu.2016.00355
Workman CJ, Dugger KJ, Vignali DAA (2002) Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation Gene-3. J Immunol 169(10):5392–5395. https://doi.org/10.4049/jimmunol.169.10.5392
Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DAA (2002) Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol 32(8):2255. https://doi.org/10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A
Workman CJ, Vignali DAA (2003) The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 33(4):970–979. https://doi.org/10.1002/eji.200323382
Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, Vignali DAA (2009) LAG-3 regulates Plasmacytoid dendritic cell homeostasis. J Immunol 182(4):1885–1891. https://doi.org/10.4049/jimmunol.0800185
Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, Du X, Tang L, He F (2014) LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res 74(13):3418–3428. https://doi.org/10.1158/0008-5472.CAN-13-2690
Zarour HM (2016) Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res 22(8):1856–1864. https://doi.org/10.1158/1078-0432.CCR-15-1849
Zhang J, Liu W, **e T, Huang L, Hu Y, Wen B, Tang P, Guo F, ** K, Zhang P, Niu L, Liu Z, Qu X (2019) Elevated LAG-3 on CD4+ T cells negatively correlates with neutralizing antibody response during HCV infection. Immunol Lett 212:46–52. https://doi.org/10.1016/j.imlet.2019.06.003
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sankpal, K., Morparia, S., Suvarna, V., Murahari, M. (2024). LAG-3 Inhibitors for the Treatment of Lung Cancer. In: Bhatt, S., Eri, R.E., Goh, BH., Paudel, K.R., Andreoli Pinto, T.d.J., Dua, K. (eds) Immunotherapy Against Lung Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-99-7141-1_8
Download citation
DOI: https://doi.org/10.1007/978-981-99-7141-1_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-7140-4
Online ISBN: 978-981-99-7141-1
eBook Packages: MedicineMedicine (R0)